Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosolized Ribavirin Schedules for RSV in Hematological Malignancies
NCT00500578Phase 4Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Feb 2003
- Primary completion
- Jan 2009
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ribavirin in respiratory syncytial virus infection (RSV) (2 arms), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Occurrences of Pneumonia at 6 years. Started Feb 2003; status: completed.
02
Drugs
ribavirin
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT00500578.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00500578.